In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Tirzepatide: a new low for bodyweight and blood glucose The Lancet Diabetes & Endocrinology Retatrutide, Retatrutide vs. Tirzepatide, Retatrutide vs. Semaglutide, Retatrutide vs. Cagrilintide Current Strategies in Managing Obesity STRIVE Obesity